Group LeaderLocation and ContactMembersLines of ResearchNotable PublicationsProjectsPhD ThesesClinical TrialsPatents and TrademarksNews
Professor Julio Bobes García
Professor of Psychiatry at the Universidad de Oviedo, Julio Bobes García is currently Head of the Psychiatry Division in the university’s Department of Medicine, and Head of the Psychiatry Department for the Health District of Oviedo (Spain). He is also principal investigator of CIBERSAM (Network Centre for Biomedical Research: Mental Health) in Oviedo, Director of ISPA’s Neuroscience research division and President of the Real Academia de Medicina del Principado de Asturias (Royal Academy of Medicine of Asturias).
His work includes teaching, research and clinical practice.
He has published over 300 articles and is author and coordinator of several books, as well as a collaborator on a large number of book chapters.
His research interests include diverse aspects of the evaluation, management, treatment and impact of a range of psychiatric disorders: addictions, and psychotic, affective, anxiety and psychophysiological disorders. He also participates actively in the study and prevention of suicidal behaviours.
He is a member of a range of scientific societies within and outside Spain, in several of which he has held leadership positions, including board member of the European Psychiatric Association (EPA) and president of: the Sociedad Española de Psiquiatría Biológica (Spanish Society of Biological Psychiatry); the Consejo Español del Cerebro (Spanish Brain Council), which is part of the European Brain Council; Socidrogalcohol (Drug-Alcohol Society); the Sociedad Española para el Estudio de los Trastornos de Personalidad (Spanish Society for the Study of Personality Disorders) and, currently, the Sociedad Española de Psiquiatría (Spanish Psychiatry Society).
He participates in the editorial boards of high-impact publications and is editor-in-chief of the Psiquiatría y Salud Mental journal (IF 2017: 2.233).
María Paz García-Portilla González
Departamento de Medicina – Área de Psiquiatría
Universidad de Oviedo
C/ Julián Clavería s/n – 33006 Oviedo, Spain.
Telephone: +34 985103553
E-mail: bobes@uniovi.es
| Name | Organisation | Activity | Euraxess classification |
|---|---|---|---|
| Álvarez Vázquez, Clara María | SESPA | Research/Clinical | CLASSIFICATION NOT AVAILABLE |
| Bascarán Fernández, María Teresa | CIBER | Research | R1 |
| Bobes Bascarán, María Teresa | Universidad de Oviedo/SESPA | Research/Clinical/Teaching | R2 |
| Bobes García, Julio | Universidad de Oviedo/SESPA | Research/Clinical/Teaching | R4 |
| Bousoño García, Manuel | Research/Clinical | R3 | |
| Dal Santo , Francesco | SESPA | Research/Clinical | R1 |
| Fernández Miranda, Juan José | SESPA | Research/Clinical/Teaching | R2 |
| García Álvarez, Leticia | Universidad de Oviedo | Research/Teaching | R2 |
| García Fernández, Ainoa | FINBA | Research | R1 |
| García-Portilla González, María Paz | Universidad de Oviedo/SESPA | Research/Clinical/Teaching | R3 |
| González Blanco, Leticia | Universidad de Oviedo/SESPA | Research/Clinical | R2 |
| Iglesias García, Celso | SESPA/Universidad de Oviedo | Research/Clinical/Teaching | R2 |
| Jiménez Treviño, Luis | Universidad de Oviedo/SESPA | Research/Clinical/Teaching | R2 |
| Martínez Cao, Clara | Universidad de Oviedo | Research | R1 |
| Menéndez Miranda, Isabel | SESPA | Research/Clinical | R2 |
| Rodríguez Revuelta, Julia | Universidad de Oviedo/SESPA | Research/Clinical/Teaching | R2 |
| Saiz Martínez, Pilar Alejandra | SESPA/Universidad de Oviedo | Research/Clinical/Teaching | R3 |
| Seijo Zazo, Elisa | SESPA | Research/Clinical/Teaching | R2 |
| Villa Díez, Rocío | SESPA | Research/Clinical | R2 |
| Díaz Fernández, Sylvia | SESPA | Research/Clinical/Teaching | No classification |
| Fernández Raposo, Cristina | FINBA | Research | No classification |
| González García-Portilla, María José | FINBA | Research | No classification |
| Suárez Álvarez, María | SESPA | Research/Clinical | No classification |
| Zurrón Madera, Paula | SESPA | Research/Clinical/Teaching | No classification |
- AUTHORS: Carli V., Hoven C.W., Wasserman C., Chiesa F., Guffanti G., Sarchiapone M., Apter A., Balazs J., Brunner R., Corcoran P., Cosman D., Haring C., Iosue M., Kaess M., Kahn J.P., Keeley H., Postuvan V., Saiz P., Varnik A., Wasserman D.
TITLE: A newly identified group of adolescents at “invisible” risk for psychopathology and suicidal behavior: Findings from the SEYLE study.
World Psychiatry. 2014;13(1):78-86. IF 14.225 - AUTHORS: Garcia-Bueno B., Bioque M., Mac-Dowell K.S., Barcones M.F., Martinez-Cengotitabengoa M., Pina-Camacho L., Rodriguez-Jimenez R., Saiz P.A., Castro C., Lafuente A., Santabarbara J., Gonzalez-Pinto A., Parellada M., Rubio G., Garcia-Portilla M.P., Mico J.A., Bernardo M., Leza J.C.
TITLE: Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: Toward an integrative inflammatory hypothesis of schizophrenia.
Schizophrenia Bulletin. 2014;40(2):376-387. IF 8.450 - AUTHORS: Garcia-Portilla M.P., Garcia-Alvarez L., Mane A., Garcia-Rizo C., Sugranyes G., Berge D. et al.
TITLE: The negative syndrome of schizophrenia: Three -underlying components are better than two.
Schizophrenia Research. 2014;166(1-3):115-118. IF 3.923 - AUTHORS: Brunner R., Kaess M., Parzer P., Fischer G., Carli V., Hoven C.W., Wasserman C., Sarchiapone M., Resch F., Apter A., Balazs J., Barzilay S., Bobes J., Corcoran P., Cosmanm D., Haring C., Iosuec M., Kahn J.-P., Keeley H., Meszaros G., Nemes B., Podlogar T., Postuvan V., Saiz P.A., Sisask M., Tubiana A., Varnik A., Wasserman D.
TITLE: Life-time prevalence and psychosocial correlates of adolescent direct self-injurious behavior: A comparative study of findings in 11 European countries.
Journal of Child Psychology and Psychiatry and Allied Disciplines. 2014;55(4):337-348. IF 6.459 - AUTHORS: Van Os J., Rutten B.P., Myin-Germeys I., Delespaul P., Viechtbauer W., Van Zelst C., Bruggeman R., Reininghaus U., Morgan C., Murray R.M., Di Forti M., McGuire P., Valmaggia L.R., Kempton M.J., Gayer-Anderson C., Hubbard K., Beards S., Stilo S.A., Onyejiaka A., Bourque F., Modinos G., Tognin S., Calem M., O’Donovan M.C., Owen M.J., Holmans P., Williams N., Craddock N., Richards A., Humphreys I., Meyer-Lindenberg A., Leweke F.M., Tost H., Akdeniz C., Rohleder C., Bumb J.M., Schwarz E., Alptekin K., Ucok A., Saka M.C., Atbagoglu E.C., Guloksuz S., Gumus-Akay G., Cihan B., Karadag H., Soygur H., Cankurtaran E.S., Ulusoy S., Akdede B., Binbay T., Ayer A., Noyan H., Karadayi G., Akturan E., Ulas H., Arango C., Parellada M., Bernardo M., Sanjuan J., Bobes J., Arrojo M., Santos J.L., Cuadrado P., Solano J.J.R., Carracedo A., Bernardo E.G., Roldan L., Lopez G., Cabrera B., Cruz S., Mesa E.M.D., Pouso M., Jimenez E., Sanchez T., Rapado M., Gonzalez E., Martinez C., Sanchez E., Olmeda M.S., De Haan L., Velthorst E., Van Der Gaag M., Selten J.-P., Van Dam D., Van Der Ven E., Van Der Meer F., Messchaert E., Kraan T., Burger N., Leboyer M., Szoke A., Schurhoff F., Llorca P.-M., Jamain S., Tortelli A., Frijda F., Vilain J., Galliot A.-M., Baudin G., Ferchiou A., Richard J.-R., Bulzacka E., Charpeaud T., Tronche A.-M., De Hert M., Van Winkel R., Decoster J., Derom C., Thiery E., Stefanis N.C., Sachs G., Aschauer H., Lasser I., Winklbaur B., Schlogelhofer M., Riecher-Rossler A., Borgwardt S., Walter A., Harrisberger F., Smieskova R., Rapp C., Ittig S., Soguel-Dit-Piquard F., Studerus E., Klosterkotter J., Ruhrmann S., Paruch J., Julkowski D., Hilboll D., Sham P.C., Cherny S.S., Chen E.Y.H., Campbell D.D., Li M., Romeo-Casabona C.M., Cirion A.E., Mora A.U., Jones P., Kirkbride J., Cannon M., Rujescu D., Tarricone I., Berardi D., Bonora E., Seri M., Marcacci T., Chiri L., Chierzi F., Storbini V., Braca M., Minenna M.G., Donegani I., Fioritti A., La Barbera D., La Cascia C.E., Mule A., Sideli L., Sartorio R., Ferraro L., Tripoli G., Seminerio F., Marinaro A.M., McGorry P., Nelson B., Amminger G.P., Pantelis C., Menezes P.R., Del-Ben C.M., Tenan S.H.G., Shuhama R., Ruggeri M., Tosato S., Lasalvia A., Bonetto C., Ira E., Nordentoft M., Krebs M.-O., Barrantes-Vidal N., Cristobal P., Kwapil T.R., Brietzke E., Bressan R.A., Gadelha A., Maric N.P., Andric S., Mihaljevic M., Mirjanic T.
TITLE: Identifying gene-environment interactions in schizophrenia: Contemporary challenges for integrated, large-scale investigations.
Schizophrenia Bulletin. 2014;40(4):729-736. IF 8.450 - AUTHORS: Garcia-Portilla M.P., Bobes-Bascaran M.T., Bascaran M.T., Saiz P.A., Bobes J.
TITLE: Long term outcomes of pharmacological treatments for opioid dependence: Does methadone still lead the pack?.
British Journal of Clinical Pharmacology. 2014;77(2):272-284. IF 3.878 - AUTHORS: Stubbs B., Vancampfort D., Bobes J., De Hert M., Mitchell A.J.
TITLE: How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview.
Acta Psychiatrica Scandinavica. 2015;:-. IF 6.128 - AUTHORS: Gonzalez-Blanco L., Greenhalgh A.M.D., Garcia-Rizo C., Egea E.F., Miller B.J., Kirkpatrick B.
TITLE: Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: A meta-analysis.
Schizophrenia Research. 2015;:-. IF 4.4530 - AUTHORS: Wasserman D., Hoven C.W., Wasserman C., Wall M., Eisenberg R., Hadlaczky G., Kelleher I., Sarchiapone M., Apter A., Balazs J., Bobes J., Brunner R., Corcoran P., Cosman D., Guillemin F., Haring C., Iosue M., Kaess M., Kahn J.-P., Keeley H., Musa G.J., Nemes B., Postuvan V., Saiz P., Reiter-Theil S., Varnik A., Varnik P., Carli V.
TITLE: School-based suicide prevention programmes: The SEYLE cluster-randomised, controlled trial.
The Lancet. 2015;385(9977):1536-1544. IF 44.002 - AUTHORS: Menendez-Miranda I., Garcia-Portilla M.P., Garcia-Alvarez L., Arrojo M., Sanchez P., Sarramea F. et al.
TITLE: Predictive factors of functional capacity and real-world functioning in patients with schizophrenia.
European Psychiatry. 2015;30(5):622-627. IF 3.912 - AUTHORS: Garcia-Portilla M.P., Garcia-Alvarez L., Saiz P.A., Al-Halabi S., Bobes-Bascaran M.T., Bascaran M.T. et al.
TITLE: Psychometric evaluation of the negative syndrome of schizophrenia.
European Archives of Psychiatry and Clinical Neuroscience. 2015;265(7):559-566. IF 4.113 - AUTHORS: Zalsman G, Hawton K, Wasserman D, van Heeringen K, Arensman E, Sarchiapone M, Carli V, Höschl C, Barzilay R, Balazs J, Purebl G, Kahn JP, Sáiz PA, Lipsicas CB, Bobes J, Cozman D, Hegerl U, Zohar J.
TITLE: Suicide prevention strategies revisited: 10-year systematic review.
The Lancet. Psychiatry. 2016; 3(7):646-59. IF 11.5880 - AUTHORS: Bonnin C.M., Torrent C., Arango C., Amann B.L., Sole B., Gonzalez-Pinto A., Crespo J.M., Tabares-Seisdedos R., Reinares M., Ayuso-Mateos J.L., Garcia-Portilla M.P., Ibanez A., Salamero M., Vieta E., Martinez-Aran A.
TITLE: Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional Outcome.
British Journal of Psychiatry. 2016;208(1):87-93. IF 6.347 - AUTHORS: Martinez-Cengotitabengoa M, MacDowell KS, Alberich S, Diaz FJ, Garcia-Bueno B, Rodriguez-Jimenez R, Bioque M, Berrocoso E, Parellada M, Lobo A, Saiz PA, Matute C, Bernardo M, Gonzalez-Pinto A, Leza JC, FLAMM-PEPs, Arango López Celso.
TITLE: BDNF and NGF Signalling in Early Phases of Psychosis: Relationship With Inflammation and Response to Antipsychotics After 1 Year.
Schizophrenia bulletin. 2016; 42(1):142-51. IF 7.5750 - AUTHORS: Banzer R., Haring C., Buchheim A., Oehler S., Carli V., Wasserman C., Kaess M., Apter A., Balazs J., Bobes J., Brunner R., Corcoran P., Cosman D., Hoven C.W., Kahn J.P., Keeley H.S., Postuvan V., Podlogar T., Sisask M., Varnik A., Sarchiapone M., Wasserman D.
TITLE: Factors associated with different smoking status in European adolescents: results of the SEYLE study.
European Child and Adolescent Psychiatry. 2017;:1-11. IF 3.2950 - AUTHORS: Jimenez E., Arias B., Mitjans M., Goikolea J.M., Ruiz V., Brat M., Saiz P.A., Garcia-Portilla M.P., Buron P., Bobes J., Oquendo M.A., Vieta E., Benabarre A.
TITLE: Clinical features, impulsivity, temperament and functioning and their role in suicidality in patients with bipolar disorder.
Acta Psychiatrica Scandinavica. 2016; 133(4):266-76. IF 6.790 - AUTHORS: Garcia-Portilla MP, Garcia-Alvarez L, Sarramea F, Galvan G, Diaz-Mesa E, Bobes-Bascaran T, Al-Halabi S, Elizagarate E, Iglesias C, Saiz Martínez PA, Bobes J.
TITLE: It is feasible and effective to help patients with severe mental disorders to quit smoking: An ecological pragmatic clinical trial with transdermal nicotine patches and varenicline.
Schizophrenia Research. 2016; 176(2-3):272-280. IF 3.986 - AUTHORS: Barzilay S., Brunstein Klomek A., Apter A., Carli V., Wasserman C., Hadlaczky G., Hoven C.W., Sarchiapone M., Balazs J., Kereszteny A., Brunner R., Kaess M., Bobes J., Saiz P., Cosman D., Haring C., Banzer R., Corcoran P., Kahn J.-P., Postuvan V., Podlogar T., Sisask M., Varnik A., Wasserman D.
TITLE: Bullying Victimization and Suicide Ideation and Behavior Among Adolescents in Europe: A 10-Country Study.
Journal of Adolescent Health. 2017;61(2):179-186. IF 3.974 - AUTHORS: Sanchez-Moreno J, Bonnin CM, González-Pinto A, Amann BL, Solé B, Balanzá-Martinez V, Arango C, Jiménez E, Tabarés-Seisdedos R, Garcia-Portilla MP, Ibáñez A, Crespo JM, Ayuso-Mateos JL, Martinez-Aran A, Torrent C., Vieta E, CIBERSAM Functional Remediation Group.
TITLE: Factors associated with poor functional outcome in bipolar disorder: sociodemographic, clinical, and neurocognitive variables.
Acta Psychiatrica Scandinavica. 2018 May 3. doi: 10.1111/acps.12894 FI 6,790 - AUTHORS: Jongsma H.E., Gayer-Anderson C., Lasalvia A., Quattrone D., Mule A., Szoke A., Selten J.-P., Turner C., Arango C., Tarricone I., Berardi D., Tortelli A., Llorca P.-M., De Haan L., Bobes J., Bernardo M., Sanjuan J., Santos J.L., Arrojo M., Del-Ben C.M., Menezes P.R., Murray R.M., Rutten B.P., Jones P.B., Van Os J., Morgan C., Kirkbride J.B., Reininghaus U., Di Forti M., Hubbard K., Beards S., Stilo S.A., Tripoli G., Parellada M., Cuadrado P., Solano J.J.R., Carracedo A., Bernardo E.G., Roldan L., Lopez G., Cabrera B., Lorente-Rovira E., Garcia-Portilla P., Costas J., Jimenez-Lopez E., Matteis M., Rapado M., Gonzalez E., Martinez C., Sanchez E., Olmeda M.S., Franke N., Velthorst E., Termorshuizen F., Van Dam D., Van Der Ven E., Messchaart E., Leboyer M., Schurhoff F., Jamain S., Frijda F., Baudin G., Ferchiou A., Pignon B., Richard J.-R., Charpeaud T., Tronche A.-M., La Barbera D., La Cascia C., Marrazzo G., Sideli L., Sartorio C., Ferraro L., Seminerio F., Loureiro C.M., Shuhama R., Ruggeri M., Tosato S., Bonetto C., Cristofalo D.
TITLE: Treated incidence of psychotic disorders in the multinational EU-GEI study.
JAMA Psychiatry. 2018;75(1):36-46. IF 15.3070
| Title | Funding Body | Reference No | Principal Investigator | Co-Investigators | Duration | Funding |
|---|---|---|---|---|---|---|
| Detection of suicidal behaviour risk through a combination of genomic and clinical approaches | Instituto de Salud Carlos III, Health Research Fund (FIS) | PI17/01433 | Pilar Alejandra Sáiz | 2018 – 2020 | €123,420.00 | |
| Construction of a clinical staging model for schizophrenia | Instituto de Salud Carlos III (FIS) | PI16/01761 | Julio Bobes | Leticia González Blanco, Isabel Menéndez Miranda, Celso Iglesias García, Eduardo Fonseca Pedrero | 2017 – 2019 | €67,155.00 |
| Training European Network: Metabolic Dysfunctions associated with the Pharmacological Treatment of Schizophrenia (TREATMENT) | European Commission – H2020-MSCA-ITN-2016 | 721236 | Angela Valverde (CSIC) | CIBERSAM – Associated Centre – G05: Julio Bobes, María Paz García-Portilla González | 2017 – 2019 | |
| Inflammatory alterations in mental diseases: the role of Nrf2 and inflammasome pathways | CIBERSAM | CIBERSAM Intramural Translational Project (2015 funding round) | Javier Rubén Caso (G19) | Pilar Lopez García (G-03), Julio Bobes García, Pilar Alejandra Saiz Martinez and Celso Iglesias García (G-05), Virginia Soria Tomas and Mikel Urretavizcaya Sarachaga (G-17), Tomás Palomo Álvarez and Noelia Guerra Martin-Polanco (G-19), Francisco Javier De Diego Adeliño (G-21) | 2015 – 2016 | €30,000 |
| Maternal prenatal stress and HPA axis sensitisation mediated by 11β-HSD2 gene epigenetic signatures and its interplay with childhood psychosocial stress in explaining psychopathology risk in adolescence | CIBERSAM | CIBERSAM Intramural Translational Project (2015 funding round) | Lourdes Fañanás Saura (G08) | María Paz García-Portilla (PI), Isabel Menéndez, Lorena de la Fuente, Plácido Llaneza, Ana Escudero | 2015 – 2016 | €25,000 |
| Validation of Apathy Evaluation Scales (AES) in patients with schizophrenia | CIBERSAM | BICIBERSAM (May 2015 funding round) | María Paz García-Portilla González | 2015 – 2016 | €8,000 | |
| The contribution of common polygenic variation to the prediction of alcohol dependency risk | PNSD (Spanish National Drugs Plan) | PI14/02037. Multicentre project | Javier Costas Costas | Gerardo Flórez Menéndez, Elisardo Becoña Iglesias, Pilar Alejandra Sáiz Martínez, Julio Bobes García, María Paz García-Portilla González, Mario Páramo Fernández, Eduardo Paz Silva, José Javier Suárez Rama | 2015 – 2017 | €83,208 |
| Validation of a clinical staging model for bipolar disorder | Instituto de Salud Carlos III (FIS) | PI14/02037. Multicentre project with one beneficiary centre | María Paz García-Portilla González | Pilar Sierra San Miguel, Belén Arranz Martí, Gemma Safont Lacal, Celso Iglesias García | 2015 – 2017 | €70,020 |
| Neuropsychological functioning and the inflammatory profile in suicidal behaviour | Instituto de Salud Carlos III (FIS) | PI14/02029. Multicentre project with one beneficiary centre | Pilar Alejandra Sáiz Martínez | María Teresa Bascarán Fernández, Hilario Blasco Fontecilla, Myriam Hernández Hernández, Mónica Martínez Cengotitabengoa, Luis Jiménez Treviño | 2015 – 2017 | €100,000 |
| Differential biomarkers of the negative dimension of schizophrenia | Instituto de Salud Carlos III (FIS) | PI13/02263. Multicentre project: Three centres in Oviedo, one centre in Langreo, Asturias | Julio Bobes | José María Pelayo Terán, Celso Iglesias García, Leticia García Alvarez | 2014 – 2016 | €120,697.50 |
| Depression, anxiety and somatic symptoms in primary healthcare centres across the world: CIE-11-AP field study | World Health Organization (WHO) | CIE-11-AP field study, RPC 565 version 2, 8/4/2013, multicentre project | Julio Bobes | Celso Iglesias García, Diego Palao Vidal, Francisco Doce Feliz, Francisco José Vaz Leal, José Carlos González Piqueras, Lola Franco Fernández, Pilar López García, Xabier Lertxundi Aginaga | 2013 – 2014 | Unfunded |
| Identification of clinical, neurocognitive and genetic prediction variables in the emergence and recurrence of suicidal behaviour in bipolar disorder | Instituto de Salud Carlos III (FIS) | PI12/00018 | Antonio Benabarre | Patricia Burón | 2013 – 2015 | €27,030 |
| Construction of a clinical staging model for bipolar disorder | Instituto de Salud Carlos III (FIS) | PI11/02493 | María Paz García Portilla | Gonzalo Galván, Olga Simón | 2012 – 2014 | €68,000 |
| Clinical and neurobiological determinants of second-episode schizophrenia: a longitudinal study of first psychotic episodes | Instituto de Salud Carlos III (FIS) | PI11/02704 | Miguel Bernardo / Manuel Bousoño | Juan María Fernández, Blanca Morales, Gonzalo Galván | 2012 – 2015 | €68,200 |
| A comparative study of the evolution of cognitive performance in relation to nicotine in patients with schizophrenia | Instituto de Salud Carlos III (FIS) | PI11/01891 | Susana Al-Halabí | Manuel Arrojo Romero, Eva Díaz Mesa, Gonzalo Galván, Luis Jiménez Treviño, María Pouso Ríos, Ramón Ramos Ríos | 2012 – 2014 | €58,118.18 |
| Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) | European Commission – 7th Framework Programme (FP7). Large-scale integrating project . Coordinated by: Rene Kahn – Utrecht University. The Netherlands | 242114 | Celso Arango | Miguel Bernardo Arroyo, Julio Bobes García, Julio Sanjuán Arias | 2009 – 2014 | €11,937,723 |
| Working in Europe to Stop Truancy Among Youth – WE-STAY | European Commission – 7th Framework Programme (FP7). Coordinated by: Danuta Wasserman | UE-10-WE-STAY-241542 | Julio Bobes | Pilar Alejandra Sáiz Martínez, Manuel Victor Bousoño Garcia, María Paz García-Portilla González, Juan María Fernandez Domínguez, Luis Jiménez Treviño, Pedro Alberto Marina González, Julia Rodríguez Revuelta, Susana Al-Halabi Diaz, María Teresa Bascarán Fernández | 01-05-2010 to 30-04-2013 | |
| Physical comorbidity in severe mental disorders: the design, application and evaluation of a programme for improving the general health of the patient | Instituto de Salud Carlos III (FIS) | PI12/00882 | Paula Zurrón Madera | José Eloy García García; Raquel Junquera Fernández; María Luisa Prieto Cedrón; Juan Carlos Illescas Escobar | 2013 – 2015 | €47,795 |
| EUropean network of national schizophrenia networks studying Gene-Environment Interactions – EU-GEI | European Commission – 7th Framework Programme (FP7). Coordinated by: Jim van Os – Maastricht University Medical Center, The Netherlands | 241909 | Celso Arango López | Miguel Bernardo Arroyo, Julio Bobes García, Angel Carracedo Alvarez, Julio Sanjuán Arias | 2010 – 2015 |
| PhD Student | Supervisors | Title | Date | Classification |
|---|---|---|---|---|
| Patricia Rodríguez Suárez | María Paz García-Portilla GonzálezJulio Bobes García | Physical health in patients with depressive disorders: a naturalistic study | October 2014 | Summa cum laude |
| Pedro Trabajo Vega | Víctor Alvarez AntuñaManuel Bousoño García | Pedro Rodriguez Ponga (1880-1916): the life and work of a psychiatrist from Langreo in Restoration Spain | June 2015 | Summa cum laude |
| Isabel Menéndez Miranda | María Paz García-Portilla GonzálezJulio Bobes García | Functional skills, evaluated using the UPSA scale, in patients with severe mental disorders (schizophrenia and bipolar disorder) | June 2015 | Summa cum laude |
| Patricia Burón Fernández | Pilar A Sáiz MartínezJulio Bobes García | Monitoring suicidal behaviours in Health District IV of Asturias | July 2015 | Summa cum laude
European Honours |
| Elisa Seijo Zazo | Fernando Seijo FernándezManuel Bousoño García
María Paz García-Portilla González |
Deep brain stimulation in patients with Parkinson’s Disease: variation in psychiatric parameters and quality of life | September 2015 | Summa cum laude
European Honours |
| Apolonia Sánchez Jiménez | Joaquín Fernández García (†)María Paz García-Portilla González | Iron deficiency: the impact upon mental health | November 2015 | Summa cum laude |
| Eva María Díaz Mesa | María Paz García-Portilla GonzálezJulio Bobes García | Adaptation to Spanish and validation of the sixth version of the Addiction Severity Index (ASI-6) | February 2016 | Summa cum laude |
| Leticia García Álvarez | Julio Bobes GarcíaMaría Paz García-Portilla González | Differential biomarkers for schizophrenia | June 2016 | Summa cum laude
European Honours |
| María Almudena Pousada González | Julio Bobes GarcíaSusana Al-Halabí Díaz | Physical comorbidity in patients with severe mental disorders: interdisciplinary follow-up and monitoring by the mental health team and primary healthcare | June 2017 | Summa cum laude |
| Leticia González Blanco | Julio Bobes GarcíaMaría Paz García-Portilla González | Oxidative stress and inflammatory balance in the early stages of schizophrenia | May 2018 | Summa cum laude
European Honours |
- Title: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
Phase: II
Funding Body: ACADIA Pharmaceuticals Inc.
Reference Number: NCT02970305
Protocol code: ACP-103-038
Duration: January 2017 – June 2019 - Title: An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression. Safety and Sustenance of Esketamine Treatment Response with Repeated Doses at Intervals Determined by Symptom Severity (SUSTAIN-3)
Phase: III
Funding Body: Janssen-Cilag
Reference Number: EUDRACT 2015-003578-34
Protocol code: 54135419TRD3008
Duration: 2017 – 2022 - Title: Interventional, Open-label, Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia.
Phase: III
Funding Body: H. Lundbeck A/S
Reference Number: EUDRACT 2015-003284-11
Protocol code: 16159B
Duration: 2017 – 2019 - Title: A 52-Week, Open-Label, Prospective, Multicentre, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilised on the Paliperidone Palmitate 1-Month Formulation
Phase: III
Funding Body: Janssen-Cilag
Reference Number: NCT02713282
Protocol code: R092670SCH3015
PI – Julio Bobes
Sub-investigators: María Paz García-Portilla González, Pilar A Saiz Martínez
Duration: 2016 – 2017 - Title: Predictors of Real-world Functioning of Schizophrenia Patients in Maintenance Treatment with Monotherapy Antipsychotics . FunREAL
Funding Body: CIBERSAM – Janssen Internacional
Duration: 2015 – 2016 - Title: Efficacy and Safety of Inhaled Loxapine Compared with IM Antipsychotic in Acutely Agitated Patients with Schizophrenia or Bipolar Disorder
Phase: IIIb
Funding Body: Ferrer Internacional, S.A.
Reference Number: EUDRA CT 2014-000456-29
Protocol code: FCD-ADA-1401
Duration: 2015 – 2016 - Title: European Long-acting Antipsychotics in Schizophrenia Trial (EULAST) – Clinical Trial –
Phase: IV
Funding Body: UMC Utrecht – Foundation European Group for Research In Schizophrenia (EGRIS)
Reference Number: NCT02146547
Duration: 2015 – 2017 - Title: Randomised, Controlled, Parallel Clinical Trial on the Efficacy of Pharmacogenetic Information Obtained With NEUROFARMAGEN in the Treatment of Patients With Mental Disorders.Funding Body: AB-BIOTICS S.A.
Reference Number: EUDRA CT 2013-002228-18
Protocol code: AB-GEN2013
Duration: 2014 - Title: A Phase 4, Non-Treatment Follow-Up For Cardiac Assessments Following Use Of Different Treatments For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders.
Reference Number: NCT01574703
Protocol code: A3051148
Duration: 2014 - Title: A Phase IV Randomised, Double-blind, Active and Placebo-controlled, Multicentre Study Evaluating the Neuropsychiatric Safety and Efficacy of 12 weeks Varenicline Tartrate 1mg Bid for Smoking Cessation in Subjects with and without a History of Psychiatric Disorders.
Reference Number: NCT01456936
Protocol code: A3051123
Duration: 2014 - Title: A Phase 4, E uropean Non-Interventional Study (NIS) in Patients with Schizophrenia Treated with Antipsychotic Long-Acting Injections (LAIs).
Protocol code: 14782A
Duration: 2013 - Title: A Prospective, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients With Bipolar I Disorder.
Reference Number: NCT01674010
Protocol code: ELND005-BPD201
Duration: 2013 - Title: A Phase 3, Open-label, Multicentre, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant.
Reference Number: NCT01436175
Protocol code: SPD489-329
Duration: 2013 - Title: The SPD489-322 Phase 3, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy, and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.
Reference Number: NCT01436149
Protocol code: SPD489-322
Duration: 2013 - Title: A Phase III, Multicentre, Randomised, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients with Persistent, Predominant Negative Symptoms of Schizophrenia Treated with Antipsychotics Followed by a 28 Week Double-blind Treatment Period.
Protocol code: WN25309
EudraCT: 2010-020467-21
Duration: 2012 – 2014 - Title: Phase III, Multicentre, Randomised, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients with Sub-optimally Controlled Symptoms of Schizophrenia Treated with Antipsychotics Followed by a 40-week Double-blind, Parallel Group, Placebo-controlled Treatment Period.
Protocol code: WN25306
Eudra CT: 2010-020616-11
Duration: 2012 – 2014
- Presentation of the Best PhD Thesis Award 2018 to Leticia González Blanco (25/9/2019)
